High-payload antibody drug conjugates for cancer
Raised to date
$500K
of $4.5M offered across 1 Form D filing
Myris Therapeutics is a Pittsburgh-area biotech developing antibody-drug conjugates (ADCs) for cancer. It uses ATRP 'growing from' polymer chemistry to build bottlebrush polymers that carry drug payloads, aiming for 50 to 300 drug molecules per antibody versus roughly eight in most clinical ADCs. The company, formerly BioHybrid Solutions, emerged from stealth under the Myris name and presented its ADC platform publicly at AACR in April 2025.
Polymer bottlebrush conjugation that improves solubility and allows drug-to-antibody ratios of 50 to 300, widening the range of usable payloads.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Oct 14, 2026 | Other | $500K/ $4.5M | Form D |
Oncology therapeutics (preclinical)
Antibody-drug conjugates whose payloads are carried on polymer bottlebrushes grown from the antibody, giving very high drug-to-antibody ratios.
Built for
Cancer patients and oncology drug development partners
